Background Only a subset of SCCHN pts benefits from anti-EGFR mAbs. Trials with pre-and
post-therapy tumor biopsies (windows studies) in treatment-naïve patients are crucial to …

5519 Background: Only a minority of SCCHN pts benefits from anti-EGFR mAbs. Trials with
pre-and post-therapy tumor biopsies are crucial to better characterize the molecular …

Background To investigate the safety and activity of cetuximab in the pre-operative treatment
of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods …

Background Cetuximab is a targeted therapy with demonstrated efficacy in the management
of head and neck squamous cell carcinoma (HNSCC). However, no laboratory assay is …

Opinion statement The survival rate for patients with advanced stages of squamous cell
carcinoma of the head and neck (SCCHN) remains poor despite multimodal treatment …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Background Studies in squamous cell carcinoma of the head and neck (SCCHN) have
shown an abnormal level of EGFR expression, which seems to be correlated with poor …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

6060 Background: Despite near universal EGFR expression in HNSCC, the anti-EGFR
antibody, cetuximab, improves survival in only 15% of patients. Activation of immune cell …

16504 Background: C is an IgG1 chimerized, monoclonal antibody that binds specifically to
the epidermal growth factor receptor, which is expressed in 90–100% of HNC. We …